GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (NAS:APTO) » Definitions » Shiller PE Ratio

Aptose Biosciences (Aptose Biosciences) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aptose Biosciences Shiller PE Ratio Historical Data

The historical data trend for Aptose Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Shiller PE Ratio Chart

Aptose Biosciences Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptose Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptose Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Aptose Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's Shiller PE Ratio falls into.



Aptose Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aptose Biosciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Aptose Biosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.44/125.4675*125.4675
=-1.440

Current CPI (Dec. 2023) = 125.4675.

Aptose Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201311 -10.173 97.182 -13.134
201402 -6.471 98.051 -8.280
201405 -6.774 99.394 -8.551
201409 0.000 99.394 0.000
201503 -3.549 99.789 -4.462
201506 -3.384 100.500 -4.225
201509 -3.017 100.421 -3.769
201512 -4.108 99.947 -5.157
201603 -4.853 101.054 -6.025
201606 -5.333 102.002 -6.560
201609 -3.558 101.765 -4.387
201612 -2.902 101.449 -3.589
201703 -2.850 102.634 -3.484
201706 -1.650 103.029 -2.009
201709 -1.650 103.345 -2.003
201712 -1.800 103.345 -2.185
201803 -3.450 105.004 -4.122
201806 -4.500 105.557 -5.349
201809 -2.400 105.636 -2.851
201812 -2.250 105.399 -2.678
201903 -2.100 106.979 -2.463
201906 -1.950 107.690 -2.272
201909 -1.800 107.611 -2.099
201912 -1.950 107.769 -2.270
202003 -2.250 107.927 -2.616
202006 -3.150 108.401 -3.646
202009 -2.250 108.164 -2.610
202012 -2.400 108.559 -2.774
202103 -2.700 110.298 -3.071
202106 -2.250 111.720 -2.527
202109 -1.950 112.905 -2.167
202112 -4.050 113.774 -4.466
202203 -1.800 117.646 -1.920
202206 -1.720 120.806 -1.786
202209 -1.590 120.648 -1.654
202212 -1.630 120.964 -1.691
202303 -2.250 122.702 -2.301
202306 -2.270 124.203 -2.293
202309 -1.760 125.230 -1.763
202312 -1.440 125.468 -1.440

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aptose Biosciences  (NAS:APTO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aptose Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences (Aptose Biosciences) Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3